Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1integrase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6461-6464

  Johns, Brian A ^a   Kawasuji, Takashi ^b   Weatherhead, Jason G ^a   Boros, Eric C ^a   Thompson, James B ^a   Garvey, Edward P ^a   Foster, Scott A ^a   Jeffrey, Jerry L ^a   Miller, Wayne H ^b   Kurose, Noriyuki ^b   Matsumura, Kenichi ^b   Fujiwara, Tamio ^b  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Antiviral; HAART; HIV Integrase; Naphthyridinone

Indexed keywords

INTEGRASE INHIBITOR; NAPHTHYRIDINONE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CHEMICAL REACTION; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80054780827     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.08.082     Document Type: Article

References (13)

1. Taiwo, B.; Murphy, R. L.; Katlama, C. Drugs 2010, 70, 1629.
2. Fransen, S.; Gupta, S.; Danovich, R.; Hazuda, D.; Miller, M.; Witmer, M.; Petropoulos, C. J.; Huang, W. J. Virol. 2009, 83, 11440.
3. Hazuda, D. J. Braz. J. Infect. Dis. 2010, 14, 513.
4. Bangsberg, D. R.; Ragland, K.; Monk, A.; Deeks, S. G. AIDS 2010, 24, 2835.
5. Hazuda, D.; Iwamoto, M.; Wenning, L. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 377.
6. Johns, B. A.; Svolto, A. C. Expert. Opin. Ther. Patents 2008, 18, 1225.
7. Boros, E. E.; Edwards, C. E.; Foster, S. A.; Fuji, M.; Fujiwara, T.; Garvey, E. P.; Golden, P. L.; Hazen, R. J.; Jeffrey, J. L.; Johns, B. A.; Kawasuji, T.; Kiyama, R.; Koble, C. S.; Kurose, N.; Miller, W. H.; Mote, A. L.; Murai, H.; Sato, A.; Thompson, J. B.; Woodward, M. C.; Yoshinaga, T. J. Med. Chem. 2009, 52, 2754.
8. Egbertson, M.;Melamed, J. Y.;Langford, H. M.; Young, S. D.
9. MT4 and PBL assays were performed according to: Kobayashi, M.; Yoshinago, T.; Seki, T.; Wakasa-Morimoto, C.; Brown, K. W.; Ferris, R.; Foster, S. A.; Hazen, R. J.; Miki, S.; Suyama-Kagitani, A.; Kawauchi-Miki, S.; Taishi, T.; Kawasuji, T.; Johns, B. A.; Underwood, M. R.; Garvey, E. P.; Sato, A.; Fujiwara, T. Antimicrob. Agents Chemother. 2011, 55, 813.
10. Recombinant HIV-1 integrase strand transfer assay: Boros, E. E.; Johns, B. A.; Garvey, E. P.; Koble, C. S.; Miller, W. H. Bioorg. Med. Chem. Lett. 2006, 16, 5668.
11. Pseudo-type HIV assay (PHIV): Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T. Antimicrob. Agents Chemother. 2008, 52, 901.
12. PAEC50 is determined using 40 mg/mL of purified human serum albumin in the pseudo-type HIV assay described in the Ref. 10
13. Therapeutic index (CC50/EC50).